All In Biotech

Drug Trial Radar · NCT05663411

A Study of SHR6508 in Secondary Hyperparathyroidism

An Open-label, Randomized, Active-Controlled Dose Titration Study to Assess the Efficacy and Safety of SHR6508 in Hemodialysis Subjects With Secondary Hyperparathyroidism

Last checked: Nov 20, 2026Latest source record: Jun 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

75

Actual

Start

Feb 24, 2023

Primary completion

Oct 31, 2023

Study completion Nov 30, 2023

Sponsor

Sponsor type
Industry
First posted
Dec 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy and safety of SHR6508 for Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.

Conditions

  • Secondary Hyperparathyroidism

Interventions

  • SHR6508Drug

    SHR6508

  • SHR6508Drug

    SHR6508

  • CinacalcetDrug

    Cinacalcet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in serum iPTHTime frame: Baseline and the efficacy period, defined as Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.